Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Propionyl-L-Carnitine (PLC) is a derivative of L-carnitine that has been investigated for its potential benefits in treating peripheral arterial disease (PAD) and certain symptoms related to arteriosclerosis, such as intermittent claudication. Several clinical studies and systematic reviews have examined its effects. PLC is thought to improve endothelial function, enhance blood flow, and increase exercise tolerance by facilitating fatty acid metabolism in mitochondria and improving energy production in ischemic muscle tissues.

Some randomized controlled trials have shown that oral supplementation with PLC can improve walking distance and reduce symptoms in patients with PAD, a common manifestation of arteriosclerosis. For example, a 2003 meta-analysis in the journal Circulation found that L-carnitine derivatives (including PLC) modestly improved pain-free walking distance compared to placebo. However, these effects are generally mild, and not all studies have demonstrated significant benefits.

While the European Society for Vascular Surgery and similar organizations acknowledge the potential supportive role of PLC in symptomatic PAD, they do not consider it first-line therapy. The overall quality of evidence is moderate, with some positive findings but also methodological limitations and inconsistent results across studies. There is little direct evidence for PLC reversing arteriosclerosis itself, but it may help manage some associated symptoms. Thus, its use is scientifically investigated but only modestly supported for this particular indication.

More about Propionyl-L-Carnitine
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Propionyl-L-Carnitine

Products containing Propionyl-L-Carnitine